Last updated on August 2019

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma


Brief description of study

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Detailed Study Description

This study employs a "basket" design to concurrently investigate DKN-01 as monotherapy and in combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC), epithelial ovarian cancer (EOC), or carcinosarcoma (malignant mixed Mullerian tumor [MMMT]. Thus, 6 distinct patient groups are being independently investigated:

  1. 300mg DKN-01 monotherapy in recurrent EEC (Group 1)
  2. 300mg DKN-01+paclitaxel in recurrent EEC (Group 2)
  3. 300mg DKN-01 monotherapy in recurrent EOC (Group 3)
  4. 300mg DKN-01+paclitaxel in recurrent EOC (Group 4)
  5. 600mg DKN-01 monotherapy in recurrent carcinosarcoma (MMMT) (Group 5)
  6. 600mg DKN-01+paclitaxel in recurrent carcinosarcoma (MMMT) (Group 6)

Clinical Study Identifier: NCT03395080

Find a site near you

Start Over

HonorHealth

Scottsdale, AZ United States
9.99miles
  Connect »